
Alnuctamab, a BCMA x CD3 T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma
Dr. Sandy Wong, University of California San Francisco, presents the long-term follow-up data for intravenous ALNUC and preliminary data for subcutaneous ALNUC in patients with relapsed or refractory multiple myeloma from the phase 1 study.
Background:
Patients with multiple myeloma who have been exposed to three classes of treatment typically have a short-lived response to subsequent therapies. ALNUC, a 2+1 BCMA x CD3 T-cell engager that binds to BCMA with bivalent binding, showed clinical effectiveness in patients with relapsed or refractory multiple myeloma who received at least three previous lines of therapy in an open-label phase 1 study (NCT03486067). The study showed that the intravenous administration of ALNUC was associated with a high rate of cytokine release syndrome (CRS), with 89% of patients experiencing any grade of CRS and 5% experiencing grade 3 or higher CRS. Given that preclinical data suggested that subcutaneous administration of ALNUC may be better tolerated, we evaluated the safety and effectiveness of subcutaneous ALNUC. This presentation includes long-term follow-up data for intravenous ALNUC and preliminary data for subcutaneous ALNUC in patients with relapsed or refractory multiple myeloma from the phase 1 study.
Conclusions:
IV administration of ALNUC was associated with durable responses in heavily pretreated pts with RRMM. SC administration widened the therapeutic index with an improved safety profile compared with IV; CRS was limited to grade 1–2 events. SC ALNUC exhibited promising dose-dependent antitumor activity with a high proportion of MRD responses. Enrollment in the phase 1 study is ongoing and updated data will be presented.
Authors:
Sandy W. Wong, MD, Noffar Bar, MD, Laura Paris, MD, Craig C Hofmeister, MD, Markus Hansson, MD, Armando Santoro, MD, Maria-Victoria Mateos, MD, Paula Rodríguez-Otero, MD, PhD, Johan Lund, MD, Cristina Encinas, MD, Andrew J. Yee, MD, Albert Oriol, MD, Claudio Cerchione, MD, Javier de la Rubia, MD, Barbara Ferstl, MD, Kristina Carlson, MD, Paz Ribas, MD, Arancha Bermúdez, MD, Isaac W. Boss, PhD, Allison Gaudy, PhD, Shaoyi Li, PhD, Kevin Hsu, PharmD, Colin D. Godwin, MD, MPhil, Michael R. Burgess, MD, PhD, Jesús San-Miguel, MD, PhD and Luciano J. Megala Costa, MD, PhD.
ASH Abstract #162: https://ash.confex.com/ash/2022/webprogram/Paper159009.html